Congenital erythropoietic porphyria (Gcnther's disease) is a rare disorder of heme biosynthesis inherited in an autosomal recessive fashion. The molecular abnormality responsible for the characteristic defect in uroporphyrinogen 111 synthase activity was investigated in two patients. For the first patient, complementary DNA was specifically amplified using the polymerase chain reaction and subsequently cloned and sequenced. Data obtained revealed the coexistence of two distinct point mutations: a T to C ORPHYRIAS ARE A group of inherited disorders P caused by specific enzymatic defects among the heme biosynthetic pathway. Congenital erythropoietic porphyria (CEP) or Gunther's disease is a rare disease that is inherited as an autosomal recessive trait. The main clinical manifestations are chronic hemolysis, severe cutaneous photosensitivity, and massive porphyrinuria due to the accumulation, in the bone marrow, peripheral blood, and other organs, of large amounts of predominantly type I porphyrins, which are not substrates for heme synthesis. Congenital erythropoietic porphyria was the first human porphyria to be described and the first to be related to a specific enzymatic defect.' A characteristic abnormality of the disease is a n 80% to 90% decrease in the activity of uroporphyrinogen I11 synthase (UROIII -S; hydroxymethylbilane hydrolase [cyclizing];
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EC.4.2.1 .75).2.3
The recent isolation and sequencing by Tsai et a14 of a full-length complementary DNA (cDNA) encoding UROIII-S, allowed us to study the enzymatic defect at the molecular level.
MATERIALS AND METHODS

Case Report
Case 1 . S.D. is a Caucasian girl born in 1975 from healthy, non-consanguinous parents; pregnancy was normal. Congenital erythropoietic porphyria was discovered shortly after her birth when she developed an intense jaundice with hepatosplenomegaly, hemolytic anemia, and red-colored urine. The diagnosis of congenital erythropoietic porphyria was confirmed by the high levels of uro-and coproporphyrin type I found in the urine, the feces, and the red blood cells. A 92% decrease in UROIII-S activity was found in 1978 in her erythrocytes (patient, 0.5 unit/mg of protein; controls, 6.0 * 2.0 units/mg of protein).5.6 M.C. is a Tunisian girl born in 1986 from healthy first cousin parents; pregnancy was normal, but delivery occurred in the 36th week. The newborn immediately developed an intense jaundice with hepatosplenomegaly and was transferred to the hospital with a diffuse bleeding and thrombocytopenia. Exchange transfusion was done. At 10-days-old, the baby showed a rash with blisters on the back of hands, and a red discoloration of the urine. Congenital erythropoietic porphyria was confirmed by the high levels of isomeric type I porphyrins found in urine, feces, and blood and a 85% decrease in erythrocyte UROIII-S activity (1.0 units/mg of protein).
Case 2.
change in codon 73 (arginine in place of a cysteine) and a C to T change in codon 53 (leucine in place of a proline). The second case was studied by hybridization with allele specific oligonucleotides and was found to be homozygous for the same mutation in codon 53. These are the first mutations to be recognized in the uroporphyrinogen 111 synthase gene from congenital erythropoietic porphyria patients. 0 1990 by The American Society of Hematology.
R N A Extraction
The lymphoblastoid cell lines were established by Epstein-Barr virus (EBV) transformation of peripheral B lymphocytes. Total RNA was prepared according to Adrian and Hutton.'
In Vitro Amplijication
Complementary DNA was obtained by reverse transcription of total cellular RNA, as described previously.' Sequences of cDNA were amplified in vitro using two specific oligonucleotides as primers: US1 (5'-GTGCCCTATAAGGACTGCCAG-3' and US4 (5'-CAGCGCTAGGTCGCTGACTCA-3'). These primers allowed the amplification of the cDNA sequence corresponding to the entire coding region of the protein (Fig 1) . The amplification process was run following the method of Saiki et a19 with minor modifications. Briefly, 100 pL of reaction mixture containing the cDNA in 50 mmol/L KCl, 20 mmol/L Tris-HC1 pH 8.4, 1.5 mmol/L MgCl,, 200 pmol/L of each dNTP, 50 pmol of each primer, and 2 units of Taq polymerase (Perkin Elmer-Cetus). The reactions were performed in a DNA thermocycler (Perkin Elmer-Cetus, Norwalk, CT) as follows: 30 cycles of denaturation at 95°C for 1 minute, annealing at 55°C for 1 minute, and elongation at 72°C for 2 minutes.
Cloning and Sequencing
The polymerase chain reaction (PCR) products obtained as described above were purified from low gelling temperature agarose with Geneclean" (Bio 101, San Diego, CA). The purified DNA was phosphorylated and blunt-ligated into Sma I-digested phophatasetreated pGEM7Zf( +) vector (Promega-Biotech, Madison, WI). Different independent clones were then sequenced by the dideoxy chain termination method. 
Oligontrclt-otide Hybridi:orion Analysis
Amplified fragments were slot-blotted on a nylon membrane and then hybridized IO allele-specific oligonucleotides (ASO) (Fig 2A) as described previously."'
RESULTS
Derermination of rhe Murari0n.r
Amplified fragments of apparently identical size were consistently obtained. both with patients' and with normal control CONAS (Fig I) . This ruled out large deletions in the coding sequence of the patients' UROIII-S gene. Subcloning of the amplified fragments was subsequently done to obtain clones from the two different alleles. Eight of these clones wereentirely sequenced. Comparison with the normal cDNA sequence' revealed that six clones carried a T to C change at nucleotide 21 7. leading to a cysteine to arginine substitution at position 73 in the protein. The two other clones carried a C to T change at nucleotide 158. leading to a proline to leucine substitution at position 53 in the protein (Fig 2) . These were the only base changes found in the different independent clones. and we concluded that each of the two groups of clonescorresponded toeach of the twoallelesof the UROIII-S gene. respectively.
Confirmation by AS0 Hybridi:arion
Hybriditations were performed on uncloned amplified fragments from the patient cDNA. Four different oligonuclcotidcs (Fig 2A) were used. As expected from the sequencing data above. the amplified fragment from the patient hybridized with all four probes (Fig 2R. line 2. and Fig 3) . Amplified fragments from normal controls only hybridized with the oligonucleotides of normal sequence (Fig 2R. lines I  and 6 ) . Only one of the mutations (53M) was found in the amplified fragment obtained from the mother. and the other mutation (73N) was found in the father. as expected from their heterozygous states (Fig 2R. lines 3 and 4 . respect ivel y ).
The four probes were further hybridized with cDVA obtained from CEP case 2. The patient cDNA only hybridized with the normal probe at position 53 and with the mutated probe at position 73 (Fig 2R. line 5 ) . These results indicate (Fig 3) that the patient is homozygous for the mutated sequence at codon 73 (arginine instead of cysteine in the protein). For personal use only. on January 30, 2018. by guest www.bloodjournal.org From
DISCUSSION
The molecular abnormality responsible for the characteristic defect in UROIII-S activity was investigated in two patients with CEP. For the first patient, DNA was specifically amplified using the PCR and subsequently cloned and sequenced. Data obtained revealed the coexistence of two distinct point mutations (Fig 3) . The fact that no other base change was found in several independent clones strongly suggested that two distinct point mutations were present in the patient mRNA. As expected, each of the patient's parents cDNA carried one of the mutations (Fig 2) .
The second case was studied by A S 0 hybridization and was found to be homozygous for the same mutation in codon 53. This is in agreement with the fact that this patient was born from consanguinous parents.
These are the first mutations recognized so far in the UROIII-S gene from CEP patients. These findings provide strong evidence that the primary defect responsible for congenital erythropoietic porphyria is a structural alteration of the UROIII-S gene, and not a disregulation of the expression of the porphobilinogen deaminase gene as previously suggested.' Our results confirm data previously obtained from enzymatic studies in CEP families where UROIII-S defect was found to be inherited as an autosomal recessive trait. 5 It is noteworthy that both mutations reported here are located in the beginning of the coding sequence and upstream and downstream, respectively, of a previously reported highly conserved sequence that could be involved in binding the pyrrolic D ring of hydroxymethylbilane, which is specifically rearranged by UROIII-S.4 Studies using expression of the mutated cDNAs are needed to clarify the consequences on the enzymatic activity. The probes described here will allow the screening of the mutations in other CEP patients. In addition, the nucleotide substitution (C to T) at position 158 suppresses a Fok I restriction site (5'-GGATG[ 13N]-3') , while the other substitution (T to C) at position 217 introduces a Mae I1 restriction site (5'-ACGT-3'). Theoretically, this could allow the identification of the mutations by analysis of the restriction fragment lengths, at least on amplified cDNA.
In families with a previously affected child, the rapid determination of the mutation(s) in the proband will now facilitate early antenatal diagnosis by DNA analysis of the trophoblast villosities." Finally, as CEP is an erythropoietic disease and affects animals also, it could be a model for future gene therapy.
